Eyenovia Inc Investor Relations Material
Latest events
Q4 2023
Eyenovia Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Eyenovia Inc
Access all reports
Eyenovia Inc operates as a commercial-stage ophthalmic technology company. Its primary focus is on the commercialization of Mydcombi, a proprietary ophthalmic spray for mydriasis (pupil dilation) composed of tropicamide and phenylephrine, and the development of the Optejet device. The Optejet is designed for use in drug-device therapeutic product candidates for conditions such as presbyopia and pediatric progressive myopia, as well as for out-licensing for additional indications. Eyenovia's approach aims to change ocular drug delivery by achieving clinical microdosing of next-generation formulations of established pharmaceutical agents through its high-precision targeted ocular delivery system, potentially offering an alternative to conventional eyedropper delivery methods. The company is headquartered in NYC and its shares are listed on the Nasdaq.
Key slides for Eyenovia Inc
Q4 2023
Eyenovia Inc
Q4 2023
Eyenovia Inc
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States